精神分裂症既往无糖尿病患者中抗精神病药暴露相关的糖尿病酮症酸中毒与糖尿病:一项全国性巢式病例对照研究
在丹麦1995至2014年既往无糖尿病的精神分裂症人群中开展巢式病例对照研究,抗精神病药暴露与糖尿病酮症酸中毒(OR 2.60;95%CI 1.06,6.38)和2型糖尿病(OR 1.64;95%CI 1.48,1.83)相关,与1型糖尿病风险呈趋势但无统计学显著性(OR 1.38;95%CI 0.84,2.29)。
要点
- 抗精神病药暴露与糖尿病酮症酸中毒风险升高相关(OR 2.60;95%CI 1.06,6.38)。
- 抗精神病药暴露与2型糖尿病风险升高相关(OR 1.64;95%CI 1.48,1.83)。
- 抗精神病药暴露与1型糖尿病风险呈趋势但无统计学显著性(OR 1.38;95%CI 0.84,2.29)。
核心结论
- 在既往无糖尿病的精神分裂症人群中,抗精神病药暴露与糖尿病酮症酸中毒和2型糖尿病相关。
- 抗精神病药相关糖尿病酮症酸中毒不仅与精神科医生相关,也与其他可能管理和收治此类患者的医生相关。
研究设计与样本
- 采用巢式病例对照研究设计,在丹麦1995至2014年既往无糖尿病的精神分裂症人群中识别糖尿病酮症酸中毒、1型糖尿病和2型糖尿病病例。
- 病例按年龄、性别和精神分裂症发病年份1:5匹配至事件发生时存活且未移民的精神分裂症对照个体。
- 使用条件logistic回归计算OR及95%CI。
主要发现
- 在29,955例精神分裂症个体中,识别出28例糖尿病酮症酸中毒、90例1型糖尿病和2140例2型糖尿病,分别匹配至对照组137、410和9861例个体。
- 抗精神病药暴露与糖尿病酮症酸中毒相关(OR 2.60;95%CI 1.06,6.38)和2型糖尿病相关(OR 1.64;95%CI 1.48,1.83)。
- 抗精神病药暴露与1型糖尿病风险呈升高趋势但无统计学显著性(OR 1.38;95%CI 0.84,2.29)。
- 糖尿病酮症酸中毒的糖尿病病因:8例为1型,14例为2型;其余6例病因无法确定,其中4例在8天内死亡,2例未领取胰岛素和口服降糖药处方。
- 所有糖尿病酮症酸中毒病例中6例有超过1次发作;所有1型糖尿病和2型糖尿病病例中分别有4例和11例至少有1次发作。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Diabetic ketoacidosis (DKA) is a potentially fatal metabolic emergency of both type 1 and type 2 diabetes. Although there is a reduced risk of type 1 diabetes in schizophrenia, the incidence of DKA is tenfold higher than that of the general population. Thus, we aimed to investigate associations between exposure to antipsychotic medication (within 3 months prior to event) and DKA, type 1 diabetes and type 2 diabetes. We also reported related, clinically relevant outcomes. METHODS: Using a nested case-control study design, we identified cases of DKA, type 1 diabetes and type 2 diabetes in a previously diabetes-naive population with schizophrenia in Denmark from 1995 to 2014. Cases were matched (by age, sex and year of schizophrenia onset) 1:5 to schizophrenic control individuals who were alive and had not emigrated prior to event. Conditional logistic regression was used to compute ORs with 95% CIs. Other outcomes included diabetes aetiology of DKA, in-hospital mortality, DKA readmissions and temporal trends of use of insulin and oral glucose-lowering agents. RESULTS: Of 29,955 individuals with schizophrenia, we identified 28 individuals with DKA, 90 with type 1 diabetes and 2140 with type 2 diabetes. These were matched to 137, 410 and 9861 individuals in the control group, respectively. Antipsychotic exposure was associated with DKA (OR 2.60; 95% CI 1.06, 6.38) and type 2 diabetes (OR 1.64; 95% CI 1.48, 1.83). A trend towards increased risk of type 1 diabetes was found but remained insignificant (OR 1.38; 95% CI 0.84, 2.29). Diabetes aetiology of DKA was type 1 in eight cases and type 2 in 14 cases. Of the remaining six cases of DKA, aetiology could not be determined, as four were fatal within 8 days and for two, no prescriptions for insulin and oral glucose-lowering agents were redeemed. Of all DKA cases, six had more than one episode of DKA, and of all type 1 diabetes and type 2 diabetes cases, four and 11, respectively, had at least one episode. Use of insulin and oral glucose-lowering agents was higher among individuals with DKA relative to those with type 1 diabetes and type 2 diabetes. CONCLUSIONS/INTERPRETATION: Antipsychotic exposure was associated with DKA and type 2 diabetes in a previously diabetes-naive schizophrenia population. Antipsychotic-associated DKA is relevant not only for psychiatrists but also for other physicians who may manage and admit such patients.
引用
- Polcwiartek C, Kragholm K, Rohde C, et al. Diabetic ketoacidosis and diabetes associated with antipsychotic exposure among a previously diabetes-naive population with schizophrenia: a nationwide nested case-control study. Diabetologia. 2017. PMID: 28593353. doi:10.1007/s00125-017-4320-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。